GW Pharma Reports Q1 2019 Financial Results and Operational Progress - Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today... read more → May 6, 2019 Ryan T.
